Division of Cardiovascular Medicine, University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA.
Cardiol Rev. 2012 May-Jun;20(3):118-29. doi: 10.1097/CRD.0b013e318239b924.
Traditional risk factors for cardiovascular disease such as systemic hypertension and hypercholesterolemia, all described more than half a century ago, are relatively few in number. Efforts to expand the epidemiologic canon have met with limited success because of the high hurdle of causality. Fortunately, another solution to current deficiencies in risk assessment-in particular, the underestimation of risk both before and after initiation of pharmacotherapy-may exist. Parallel to the investigation of novel biomarkers, such as high-sensitivity C-reactive protein, ongoing research has yielded improved metrics of known causative conditions. This evolution of traditional risk factors, heralded by measures such as ambulatory blood pressure, central hemodynamics, low density lipoprotein particle concentration, genetic testing, and "vascular age," may better address the detection gap in cardiovascular disease.
传统的心血管疾病风险因素,如半个多世纪前就已描述的系统性高血压和高胆固醇血症,相对较少。由于因果关系的高门槛,扩大流行病学规律的努力仅取得了有限的成功。幸运的是,另一种解决当前风险评估缺陷的方法可能存在,特别是在药物治疗开始之前和之后的风险低估。与对新型生物标志物(如高敏 C 反应蛋白)的研究并行,对已知致病条件的改进指标的研究也取得了进展。这种传统风险因素的演变,以动态血压、中心血流动力学、低密度脂蛋白颗粒浓度、基因检测和“血管年龄”等指标为标志,可能更好地解决了心血管疾病检测方面的差距。